EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients

Susana Mellor-Pita, Pablo Tutor-Ureta, Paula Velasco, Aresio Plaza, Itziar Diego iD, José Vázquez-Comendador, Ana Paula Vionnet, Pedro Durán-Del Campo, Víctor Moreno-Torres iD, Juan Antonio Vargas, Raquel Castejon iD

Viruses · 2024

DOI: 10.3390/v16071071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Susana Mellor-Pita und 10 weiteren Autor:innen. Beteiligte Einrichtung: Systemic Autoimmune Diseases Unit, Department of Internal Medicine, IDIPHIM (Puerta de Hierro University Hospital Research Institute), Hospital Unive…. Hauptthemen laut MEDLINE: COVID-19, beta 2-Glycoprotein I, Immunoglobulin A, Thrombosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Comunidad de Madrid, Comunidad de Madrid under the HealthstartPlus Program, REACT-EU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with COVID-19 may develop a hypercoagulable state due to tissue and endothelial injury, produced by an unbalanced immune response. Therefore, an increased number of thromboembolic events has been reported in these patients. The aim of this study is to investigate the presence of antiphospholipid antibodies (aPL) in COVID-19 patients, their role in the development of thrombosis and their relationship with the severity of the disease. In this retrospective study, serum samples from 159 COVID-19 patients and 80 healthy donors were analysed for the presence of aPL. A total of 29 patients (18.2%) and 14 healthy donors (17.5%) were positive for aPL. Nineteen COVID-19 patients (12%) but no healthy donor presented a positive percentage of the IgA isotype aPL. IgA anti-β2-glycoprotein I antibodies (anti-β2GPI) were the most frequent type (6.3%) in patients but was not detected in any healthy donor. The positivity of this antibody was found to be significantly elevated in patients with thromboembolic events (25% vs. 5%, p = 0.029); in fact, patients with positive IgA anti-β2GPI had an incidence of thrombosis over six times higher than those who had normal antibody concentrations [OR (CI 95%) of 6.67 (1.5–30.2), p = 0.014]. Additionally, patients with moderate-severe disease presented a higher aPL positivity than patients with mild disease according to the Brescia (p = 0.029) and CURB-65 (p = 0.011) severity scales. A multivariate analysis showed that positivity for IgA anti-β2GPI is significantly associated with disease severity measured by CURB-65 [OR (CI 95%) 17.8 (1.7–187), p = 0.0016]. In conclusion, COVID-19 patients have a significantly higher positive percentage of the IgA isotype aPL than healthy donors. IgA anti-β2GPI antibodies were the most frequently detected aPL in COVID-19 patients and were associated with thrombosis and severe COVID-19 and are thus proposed as a possible marker to identify high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19beta 2-Glycoprotein IImmunoglobulin AThrombosisAntibodies, AntiphospholipidBiomarkersSARS-CoV-2Severity of Illness IndexHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedAged, 80 and over

Stichwörter der Autor:innen

COVID-19antiphospholipid antibodiesseveritythrombosis

Substanzen

beta 2-Glycoprotein IImmunoglobulin AAntibodies, AntiphospholipidBiomarkers

Autor:innen und Institutionen

  • Systemic Autoimmune Diseases Unit, Department of Internal Medicine, IDIPHIM (Puerta de Hierro University Hospital Research Institute), Hospital Universitario Puerta de Hierro Majadahonda, 28222 Madrid, Spain.
  • Department of Medicine, Facultad de Medicina, Universidad Autónoma de Madrid, 28029 Madrid, Spain.
  • Department of Immunology, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Madrid, Spain.

ORCID-Profile: Itziar Diego, Víctor Moreno-Torres, Raquel Castejon

Förderung

  • Comunidad de Madrid
  • Comunidad de Madrid under the HealthstartPlus Program, REACT-EU

Zitieren

APA

Mellor-Pita, S., Tutor-Ureta, P., Velasco, P., Plaza, A., Diego, I., Vázquez-Comendador, J., Vionnet, A. P., Durán-Del Campo, P., Moreno-Torres, V., Vargas, J. A., & Castejon, R. (2024). IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients. Viruses. https://doi.org/10.3390/v16071071

Vancouver

Mellor-Pita S, Tutor-Ureta P, Velasco P, Plaza A, Diego I, Vázquez-Comendador J, et al. IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients. Viruses. 2024. doi:10.3390/v16071071

BibTeX
@article{MellorPita2024,
  author = {Mellor-Pita, Susana and Tutor-Ureta, Pablo and Velasco, Paula and Plaza, Aresio and Diego, Itziar and Vázquez-Comendador, José and Vionnet, Ana Paula and Durán-Del Campo, Pedro and Moreno-Torres, Víctor and Vargas, Juan Antonio and Castejon, Raquel},
  title = {IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16071071}
}
Kostenlos starten →